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Abstract
The NEU1 gene is the first identified member of the human sialidases, glycohydrolitic enzymes that remove the terminal
sialic acid from oligosaccharide chains. Mutations in NEU1 gene are causative of sialidosis (MIM 256550), a severe lysosomal
storage disorder showing autosomal recessive mode of inheritance. Sialidosis has been classified into two subtypes:
sialidosis type I, a normomorphic, late-onset form, and sialidosis type II, a more severe neonatal or early-onset form. A total
of 50 causative mutations are reported in HGMD database, most of which are missense variants. To further characterize the
NEU1 gene and identify new functionally relevant protein isoforms, we decided to study its genetic variability in the human
population using the data generated by two large sequencing projects: the 1000 Genomes Project (1000G) and the NHLBI
GO Exome Sequencing Project (ESP). Together these two datasets comprise a cohort of 7595 sequenced individuals, making
it possible to identify rare variants and dissect population specific ones. By integrating this approach with biochemical and
cellular studies, we were able to identify new rare missense and frameshift alleles in NEU1 gene. Among the 9 candidate
variants tested, only two resulted in significantly lower levels of sialidase activity (p,0.05), namely c.650T.C and c.700G.A.
These two mutations give rise to the amino acid substitutions p.V217A and p.D234N, respectively. NEU1 variants including
either of these two amino acid changes have 44% and 25% residual sialidase activity when compared to the wild-type
enzyme, reduced protein levels and altered subcellular localization. Thus they may represent new, putative pathological
mutations resulting in sialidosis type I. The in silico approach used in this study has enabled the identification of previously
unknown NEU1 functional alleles that are widespread in the population and could be tested in future functional studies.
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Introduction
The NEU1 gene (MIM 608272) is the first identified member of
the human sialidases [1]. Sialidases (EC 3.2.1.18) are a family of
glycohydrolitic enzymes that remove the terminal sialic acid from
oligosaccharide chains of various natural substrates. In human
four sialidase enzymes (NEU1–4) have been identified so far, each
protein with a distinct substrate specificity and subcellular
localization: the lysosomal NEU1, the cytosolic NEU2, the
membrane-bound NEU3 and NEU4 [2]. All of them share the
b-propeller structure organized in six blades, each composed of
four antiparallel b-sheets, typical of sialidases [3]. A recent study
reconstructing the evolution of the sialidase protein family in
Metazoa confirmed the high conservation of this structure and the
key features of sialidase active site [4]. Essential catalytic residues
are strictly conserved and comprise: three Arg, that bind the
carboxylate group common to all sialic acids, a Tyr/Glu
nucleophile pair and an Asp that acts as the acid/base catalyst
[2]. Mutations in NEU1 gene have been identified in patients
affected by neuraminidase deficiency or sialidosis (MIM 256550), a
severe lysosomal storage disorder showing autosomal recessive
heritability. Defective NEU1 enzymatic activity in the lysosomes
causes accumulation of sialylated compounds, such as gangliosides
and glycoproteins that results in severe cytotoxicity and cell death
[5,6]. Sialidosis affects approx. 1/4,200,000 individuals and is
classified in two subtypes [7]. Sialidosis type I is a milder, late-
onset, normosomatic form of the disorder, characterized by visual
defects, myoclonus syndrome, cherry-red oculo-macular spots,
ataxia, hyperreflexia, and seizures. Sialidosis type II is the severe
early-onset form, associated with dysostosis multiplex, Hurler-like
phenotype, mental retardation, and hepatosplenomegaly. The age
of onset and severity of clinical manifestations correlate with the
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sialidase residual activity, with type II sialidosis usually presenting
a completely inactive enzyme [2,8,9]. The association of NEU1
with PPCA, a protein encoded by the CTSA gene, is essential for
the correct trafficking to lysosomes, where the sialidase enzyme is
processed to its active form [10]. Thus, NEU1 variants resulting in
a defective interaction with PPCA also lead to disease, even if the
essential residues for the catalytic activity are not affected
[5,11,12]. To date, 50 causative mutations are reported in
HGMD [13] database, most of which are missense variants,
suggesting a high allelic heterogeneity. Recent studies have also
defined a role for NEU1 in various multifactorial diseases, such as
atherosclerosis [14], obesity [15], diabetes [16,17] and Alzheimer’s
disease [18], as well as in other important cellular processes, such
as cancer and immunological response [19]. To further charac-
terize the NEU1 gene and identify functionally relevant protein
isoforms, we decided to study its genetic variability in the human
population. This approach is today made feasible by the huge
amount of genomic data freely available to the scientific
community, generated by large sequencing projects. The 1000
Genomes Project (1000G) [20] provides high-coverage exome
sequences and middle or low-coverage genome sequences from
about 1000 healthy individuals, while the NHLBI GO Exome
Sequencing Project (ESP) [21] provides high-coverage exome
sequences from about 6500 individuals, including both healthy
controls and subjects affected by heart, lung and blood disorders.
These studies rely on next generation sequencing (NGS) technol-
ogies to generate the complete sequence of genome/exome,
allowing the identification of single nucleotide polymorphisms
(SNPs), small insertion/deletions (indels) and large genomic
rearrangements (CNVs). The samples analyzed are collected from
individuals of different ethnicity allowing the estimation of allele
frequencies in the overall population as well as in the single
ancestry groups. Overall, the two datasets result in a cohort of
7595 individuals with detailed genomic data, making possible to
identify rare variants, as well as to dissect population specific ones.
Integrating this approach with biochemical and cellular studies led
us to the identification in NEU1 gene of new rare alleles carrying
missense and frameshift mutations responsible for impaired
enzyme activity, thus representing new putative causative muta-
tions responsible for sialidosis.
Materials and Methods
Retrieving of NEU1 variants from 1000G and ESP6500
databases
Single nucleotide variants (SNV) for NEU1 human gene
(NEU1, NM_000434.3) were recovered directly from the data
available from the 1000G and ESP6500 public repository, updated
at March 2013. The genomic coordinates of the gene were used to
extract the variants of interest from the VCF (variant call format)
files containing global SNVs and indels annotations. Variants in
NEU1 gene were annotated using wANNOVAR [22] to obtain
complete functional information. In house developed tools were
used to manipulate the VCF files and analyze data on genotype
and allele frequency for the global population and for the 4
subpopulations described in the 1000G dataset (African, AFR;
American, AMR; European, EUR; Asiatic, ASN).
Analysis of variants and identification of new candidate
mutations in NEU1
Variants identified in the NEU1 exons were categorized in
UTR, synonymous, missense, stop-lost, splice-site, stop-gained and
frameshift based on functional annotations from wANNOVAR
[22]. The latter 3 groups are subsequently referred to as Loss of
Function (LoF) variants. The functional impact of missense SNVs
was predicted using three different software: PolyPhen 2 [23],
SIFT [24] and VEP tool [25]. The conservation score for every
amino acid position in NEU1 was calculated using ScoreCons [26]
and the multiple alignment provided in [4]. According to gene
data from RefSeq database, we also divided the identified variants
based on the exon in which they are located. Based on NEU2
crystal structure from RCSB database (1VCU) and the predicted
structure of NEU1 protein derived by homology modeling, we also
grouped genetic variants in three categories, namely strand, helix
or other (comprising turn, bend and disordered portion),
according to the position in which they fall in the generated 3D
model. Significance of enrichment for overall SNVs or non
synonymous variants was tested in every category applying a
binomial test. For exon categories the total dimension of the gene
was considered for calculation, while for secondary structure
categories the dimension of the coding sequence (CDS) was used.
When testing enrichment of non synonymous variants we used the
number of non synonymous sites instead of the total number of
bases to calculate the success probability and the number of trials
for each category.
As already mentioned, data from 1000G and ESP6500
databases allow for the study of allele frequencies and genotypes
in global dataset as well as in defined subpopulations. American
(AMR), African (AFR) and European (EUR) subpopulations were
considered in the 1000G dataset, as these 3 groups represent the
better overlap with the 2 subpopulations of African American (AA)
and European American (EA), present in the ESP6500 dataset.
We analyzed data from these subpopulations and identified as
population specific those variants with a MAF (Minor Allele
Frequency) .5% in one of the considered subpopulations and
MAF,1% in all the others.
From the missense SNVs identified in NEU1 gene, we selected
a set of novel candidate mutations for subsequent functional
studies according to this parameters: MAF,1%, present only in
heterozygous state, not already reported in HGMD [13] database,
predicted as damaging by at least 2 out of the 3 functional
prediction algorithms described above. Location of the relevant
variants identified within the NEU1 mRNA sequence is shown in
Figure S2.
NEU1 structure prediction and analysis
Prediction of the human NEU1 3D structure was obtained by
homology modeling using I-Tasser [27] and the known crystal
structure of human NEU2 (1VCU). Refinement of the secondary
structure elements, i.e. beta-strands and alpha-helices, has been
carried out based on MUSCLE alignment and the positions of
these structural elements in human NEU2. The already known
sialidosis mutations together with our new candidates were placed
on the predicted structure in order to assess their possible impact
on the structural conformation of human NEU1, as well as the
position of the corresponding side chains (inner core or surface of
the polypeptide). All structure manipulations have been carried
out using PyMol (The PyMOL Molecular Graphics System,
Version 1.5.0.1 Schro¨dinger, LLC).
Generation of NEU1 and PPCA constructs
Complete CDS of human NEU1 (NM_000434.3) and CTSA
(alias PPCA, NM_001127695.1) genes were amplified from 50 ng
of human liver cDNA using primers containing the appropriate
restriction sites (see Table S1 in File S1) and cloned into pIRES-
hrGFP-1a and pcDNA3.1-Myc/HIS-a vectors, respectively. Both
genes were cloned with their own stop codon, so that the expressed
proteins do not contain any tag epitope. The pIRES-hrGFP-1a
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vector promotes the expression of a polycistronic mRNA encoding
the gene of interest together with a humanized form of GFP,
which allows for visual assessment of transfection efficiency in
mammalian cells. The 9 single base substitutions selected for
functional studies were inserted into the NEU1 wild-type CDS
using the QuickChange II SiteDirected Mutagenesis kit (Agilent)
and the desired mutagenesis primer pairs (see Table S1 in File S1),
according to manufacturer protocol. Nine mutated constructs
were generated: pIRES-G88A-hrGPF, pIRES-L90F-hrGPF,
pIRES-P210A-hrGPF, pIRES-V217A-hrGPF, pIRES-T222M-
hrGPF, pIRES-D234N-hrGPF, pIRES-G248S-hrGPF, pIRES-
G252S-hrGPF, pIRES-S351R- hrGPF.
Cell culture and transfection
COS7 cells (cell line acquired from ATCC) were cultured in
DMEM (Dulbecco’s modified Eagle’s medium) (EuroClone)
containing 4 mM L-glutamine, 100 units/ml penicillin, 100 mg/
ml streptomycin and 10% (v/v) fetal bovine serum and were
maintained at 37uC and 5% CO2 in a humidified incubator. Cells
were co-transfected with pcDNA3.1 PPCA and pIRES hrGPF-1a
vector containing either wild-type or mutagenized NEU1 CDS
(constructs described above) in a 1:1 ratio (mol:mol). Transfections
were performed in serum-free medium (OptiMEM) employing
FuGENE HD (Promega) as transfectant agent. After 24 h
transfection the medium was changed and after further 24 h cells
were harvested. In all experiments, transfection efficiency of
NEU1 constructs was assessed by the ratio of GFP positive cells on
total cells counted in 3 different areas of the culture dish.
Confocal microscopy analysis
COS7 cells were seeded on to glass coverslips and after 24 h
were co-transfected with pcDNA3.1 PPCA and pIRES NEU1-
hrGPF-1a (wild-type or V217A, D234N mutants) as indicated
above. After 24 h transfection the medium was changed and after
further 24 h cells were washed three times with PBS containing
1 mM MgCl2 and 1 mM CaCl2 (PBS
++), fixed and permeabilized
with cold methanol for 10 min and acetone for 1 min. After three
washes and saturation with 1% BSA in PBS++ (PBS++/BSA), glass
coverslips were incubated with the following primary antibody:
rabbit anti-NEU1, Rockland 1:500, mouse anti-LAMP1, BD
Pharmigen 1:200, mouse anti-PDI, STRESSGEN 1:200. Subse-
quently, cells were washed and incubated with the following
secondary antibody: Donkey anti-rabbit Alexa-555 and goat anti-
mouse Alexa-405 1:300 (Molecular Probes, Invitrogen) diluted in
PBS++/BSA. Finally, specimens were mounted using Dako
Cytomation Fluorescent Mounting Medium and analyzed using
the confocal system LSM-510 META (Carl Zeiss). Images were
processed with LSM Image Browser (Carl Zeiss) and Adobe
Photoshop software.
Western-blot and densitometric analysis
Proteins samples (10 mg) were separated by SDS/10% PAGE
and transferred to a Hybond-P PVDF membrane (GE Health-
care). Membranes were then blocked, washed and incubated with
the following primary antibody: rabbit anti-NEU1 1:500 (Rock-
land), rabbit anti-PPCA 1:250 (Rockland) and mouse anti-a-
tubulin 1:16000 (Sigma). Detection of the immunocomplexes was
performed using appropriate HRP (horseradish peroxidase)-
conjugated secondary antibodies and an enhanced chemilumines-
cence-based system (SuperSignal West Pico Chemiluminescent
Substrate; Pierce). Focusing on the NEU1 mutants V217A and
D234N, a more detailed analysis was conducted on PPCA protein.
All the biological replicates from each NEU1 WT, V217A and
D234N were loaded on a single SDS-PAGE gel, together with a
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common reference loaded in all the three gels to allow for
comparison of protein signals between the three different
experiments. The common reference was obtained pooling
together 5 ml from all the cell extracts from wild-type NEU1 co-
transfection experiments. Western-blots with anti-PPCA and anti-
a-tubulin antibodies were then performed as described above,
followed by densitometric analysis using GelPro 3.1 software
(Media Cybernetics). We then normalized values obtained for
PPCA using the correspondent a-tubulin signals. Normalized
PPCA signals for WT, V217A and D234N samples were finally
divided for the normalized PPCA signal of the corresponding
reference sample, resulting in comparable values of PPCA protein
level. The mean of relative normalized PPCA signals was 1.04
with a confidence interval 95% of 0.62. Samples showing values
below the confidence interval were discarded from sialidase
activity study.
Sialidase activity assay and protein determination
The enzymatic activity in total cell lysates was determined as
previously described [1] using 1 mM 4MU-NeuAc (4-methylum-
belliferyl-N-acetyl-a-D-neuraminic acid, Sigma) as substrate. As-
says were performed in triplicate with 10 ml sample volume in a
final volume of 30 ml. Samples were incubated at 37uC for 30 min.
Reactions were stopped using 0.2 M Glycine/NaOH pH 10.8 and
activity was measured using Jasco FP-770 Spectrofluorimeter.
Fluorescent intensity was referred to a standard concentration
curve of 4MUB (4-methylumbelliferone). Protein concentration
was determined by dye-binding assay (Coomassie Protein Assay
Reagent, SIGMA) according to manufacturer’s manual. A
standard two-tailed t-test was calculated for every mutant taking
into account all the replicated experiments to assess the
significance of enzymatic activity variation compared to the
wild-type NEU1. When calculating the enzymatic activity of
V217A and D234N mutant proteins, 3 samples with significant
lower level of normalized PPCA protein (determined as described
above) were discarded resulting in a final dataset of 5 biological
replicates for each mutant.
Results
Genetic variations in NEU1 gene
Searching for single nucleotide variants (SNVs) in the 1000G
and ESP6500 databases, we retrieved a total of 63 SNVs in NEU1
gene. Among the 44 SNVs within the gene exons, 10 are located in
the UTRs regions and 34 in the coding DNA sequence (CDS).
Considering the CDS of the NEU1 gene, the mutational rate
resulted in 0.034 with a dN/dS ratio of 0.29. A summary of all the
SNVs present in the NEU1 gene, grouped by functional
categories, is given in Table 1.
Since we are mainly interested in variants affecting the function
of the NEU1 enzyme, as possible pathological alleles in sialidosis,
we focused our further analysis only on SNVs occurring in the
CDS of this gene. Overall, we identified 17 synonymous variants,
16 missense substitutions and 1 small indel generating a frameshift.
We failed to identify nonsense substitutions as well as variants
altering a splicing site. The synonymous variants are listed in
Table 2 with detailed annotations, while the 16 missense and the
single frameshift variants identified are reported in Table 3.
Using the information available from 1000G and ESP6500
databases, we also retrieved allele frequencies and genotype counts
for the 16 missense variants and the single frameshift variant
reported in NEU1 gene (Tables S2 and S3 in File S1). All NEU1
missense variants are rare (MAF,1%) and present only in
heterozygous state, with the exception of the missense variant
c.263G.C, resulting in the p.G88A amino acid substitution. This
variant has a MAF of 2 and 2.6% and is present in homozygous
state in 1 and 7 individuals in the global populations from 1000G
and ESP6500, respectively.
Interestingly, this SNV shows a population specific distribution,
being common only in the African population from the 1000G
Table 2. Synonymous variants in NEU1 CDS.
Genomic coordinate (hg19) dbSNP 139 ID Nucleotide change in CDS GERP score
6:31830455 rs141879244 c.99G.A 0.15
6:31829190 rs115468005 c.390T.C 210.3
6:31829178 rs142833447 c.402C.T 210.3
6:31829172 rs41267074 c.408G.A 1.11
6:31829148 rs114405905 c.432C.T 2.3
6:31829112 rs143737826 c.468C.T 1.3
6:31829094 rs115588976 c.486C.T 1.6
6:31828986 rs140168128 c.594T.C 23.17
6:31828366 rs145784816 c.648C.T 22.83
6:31828348 rs370667977 c.666G.A 23.46
6:31828315 rs188562197 c.699C.T 28.05
6:31828288 rs376599274 c.726C.T 29.19
6:31828267 rs114143271 c.747C.T 2.37
6:31827904 rs201379546 c.936G.A 3.6
6:31827901 rs149992593 c.939C.T 27.22
6:31827637 rs150864071 c.1107C.A 4.46
6:31827505 rs114618932 c.1239G.A 23.45
NEU1 cDNA sequence refers to NM_000434.3. GERP (Genomic Evolutionary Rate Profiling) score measures the level of conservation for the indicated nucleotide
(see Methods).
doi:10.1371/journal.pone.0104229.t002
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dataset (MAF 10%) and in African-American population from
ESP6500 dataset (MAF 7.2%). In the other population subgroups
it shows MAF,1%, and it is present only in heterozygous state
(see Tables S2 and S3 in File S1).
Based on the NEU2 protein structure and the structural models
predicted for the other human sialidases, we grouped the NEU1
variants according to secondary structural elements (Table 4 and
Figure 1). Only structural elements connecting antiparallel beta-
strands resulted significantly enriched in missense variants
(p 0.011). Based on the distribution of the identified SNVs within
the NEU1 gene and the corresponding protein (Table 5 and
Figure 1), we found a significant enrichment of variants (15) in
exon 4 (p 7.34 E-06), while the number was significantly lower in
exon 6 (p 0.002). Figure 1 also shows the conservation score
(calculated by ScoreCons) for every amino acid position and a
schematic representation of the predicted secondary structure of
the NEU1 protein. Notably, most of the identified missense
variants are located at low conserved positions within the regions
connecting the antiparallalel beta-strands.
Identification of candidate variants in NEU1 for in vitro
studies
Among all NEU1 gene variants, we selected 8 missense SNVs,
predicted to be potentially damaging, for in vitro functional
studies. These SNVs are rare (MAF,1%), present only in
heterozygous state and not previously known as causative
mutations in sialidosis. To this group of variants we added the
c.263G.C SNV described above, because of its population-
specific distribution. Thus, a total of 9 variants (marked with * in
Table 3) were subjected to in vitro functional studies.
We also identified a single frameshift insertion c.759_760insGA
that alters the wild-type protein from amino acid 254 onward. Due
to the dramatic effect of this variant on the protein, we chose not
to include it in our in vitro assays. The 9 candidate missense
variants were positioned within the NEU1 structural model to
assess their impact on the protein structure and their position
relative to the active site (Figure 2A and 2B). A close-up image of
the position of p.V217A and p.D234N amino acid substitutions
relative to other amino acids previously known to be involved in
NEU1-PPCA interaction [28] is shown in Figure 2C. Of these 9
missense variants, seven affect amino acids located near the
putative contact region between NEU1 and PPCA as proposed in
[28]: P210, V217, T222, D234, G248, G252, S351.
Enzymatic activity assays and immunoblotting of NEU1
mutants
COS7 cells were co-transfected with the wild-type and mutants
NEU1 cDNAs together with the human PPCA cDNA, which is
essential for the efficient lysosomal compartmentalization and
catalytic activation of NEU1 [2,12]. The sialidase activity of the
individual NEU1 variant proteins expressed in COS7 cells was
calculated as the average of 8 independent experiments, that gave
comparable transfection efficiency (22%63), based on GFP
expression (Figure 3A). Immunoblotting of transfected cell lysates
with anti-NEU1 antibodies showed the expected bands of 40 and
46 kDa, reflecting differences in the extent of glycosylation of the
NEU1 proteins, as previously reported [1,29] (Figure 3B). As
expected, transfection of wild-type NEU1 or PPCA cDNAs alone
did not result in a significant increase in sialidase activity
(Figure 3A). Instead, co-transfection of wild-type NEU1 and
PPCA resulted in a 16.665.9 fold increase in sialidase activity
compared to non-transfected cells, corresponding to
18766414 nmols h21 mg21. Co-transfection of all 9 NEU1
candidate variants with PPCA also led to a significant increase
in sialidase activity compared to non-transfected cells. Neverthe-
less, the two variants c.650T.C and c.700G.A showed
significantly lower levels of sialidase activity (p,0.05) than the
wild-type NEU1 (Figure 3A). Immunoblotting analysis confirmed
that the protein levels of these two NEU1 mutants were
substantially decreased compared to the levels of the wild-type
protein and the other mutants (Figure 3B). After discarding the
samples with low expression levels of PPCA (figure S1), we
determined that the V217A and D234N NEU1 mutants had a
specific activity of 7936233 and 458697 nmols h21 mg21,
respectively. Thus, these two NEU1 mutants retained only 44%
and 25% of the sialidase activity of the wild-type enzyme.
Subcellular localization of NEU1 mutants V217A and
D234N
Confocal microscopy analysis of COS7 cells transfected with
wild-type NEU1 showed a distribution of the protein mainly
organized in vesicular structures (Figure 4A), colocalizing with
the lysosomal marker LAMP1 (Figure 4C). Interestingly, cells
Figure 1. Distribution of variants identified in NEU1. Schematic representation of NEU1 protein, with amino acid position on the X axis. Black
vertical lines divide the 6 exons of NEU1 gene. Line graph indicates the conservation score for each amino acid position as calculated by ScoreCons.
The identified missense variants are represented as squares, with Y values corresponding to PolyPhen score. The missense variants already identified
as pathological alleles in sialidosis are represented as diagonal crosses. Below the graph, schematic representation of NEU1 structural elements: full
color blocks represent beta-strand elements, while crossed blocks represent helices. Color code identifies the 6 blades of the b-propeller structure as
described in [35]. Gray boxes represent the Asp-box elements and essential catalytic residues are indicated with dots and their residue number.
Positions of all elements are relative to the amino acid position in the graph above.
doi:10.1371/journal.pone.0104229.g001
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expressing either V217A or D234N NEU1 mutants showed a
different subcellular distribution of these proteins, without evident
colocalization with LAMP1 (Figure 4F and 4I), and a labeling
that appears concentrated in reticular and filamentous structures,
suggestive of the endoplasmic reticulum (Figure 4D and 4G). To
confirm these results, we also analyzed the distribution of wild-
type, V217A and D234N NEU1 proteins in relation to PDI as
ER marker (Figure 5) and areas of significant colocalization have
been found only for the two mutant forms of NEU1 (Figure 5C, F
and I).
Discussion
Genetic variability in NEU1 and identification of rare NEU1
alleles
The analysis of NEU1 genetic variability in public data from
large sequencing programs allowed us to recover a total of 63
Figure 2. NEU1 structure analysis and localization of the 9 candidate missense mutations. Top (A) and lateral (B) views of the structural
model of NEU1 protein. The two amino acids V217 and D234, identified in this work as affected by new putative pathological mutations, are shown in
red; the 7 amino acids affected by the other candidate missense variants tested are shown in green. Other amino acids already reported as mutated
in sialidosis and likely involved in NEU1-PPCA interaction [28] are shown in blue. The black arrow in (B) indicates the side of the catalytic crevice. (C)
Detailed view of the localization of V217 and D234. These two amino acids, together with G218, L231, W240, G243 and A298 define a region of the
NEU1 protein that could represent an important site in the surface interaction with PPCA partner.
doi:10.1371/journal.pone.0104229.g002
Figure 3. Sialidase activity assay and immunoblotting analysis. (A) Sialidase specific activity calculated for COS7 cells non transfected (NT),
transfected with NEU1 wt alone (NEU1), PPCA alone (PPCA), NEU1 wt and PPCA (WT) and NEU1 mutants and PPCA. V217A and D234N mutant
proteins resulted in a significant reduction in sialidase activity (p,0.05, marked with *). (B) Immunoblotting for PPCA and NEU1 proteins in each
sample. NEU1 showed the expected signals between 40 and 46 kDa, corresponding to different glycosylation states; PPCA showed the expected
signal at 32 kDa, corresponding to the heavy peptide of the active form of the protein. a-tub was used for protein loading normalization. The image
is representative of 3 replicate experiments.
doi:10.1371/journal.pone.0104229.g003
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single nucleotide variants (SNVs), 44 of them in the exon regions,
including 17 with potential functional impact, namely missense or
loss of function (LoF) variants (Table 1). The NEU1 gene shows a
relatively small number of SNVs that alter the sequence of the
encoded protein. This has to be expected considering the essential
physiological role of this enzyme, whose impaired activity leads to
sialidosis, a severe mendelian disease. The high level of negative
selective pressure acting on NEU1 gene is also confirmed by a low
dN/dS value [30]. SNVs appear to distribute unevenly throughout
the NEU1 gene (Table 5 and Figure 1), with exon 4 significantly
enriched in variants. Intriguingly, this exon encodes a region of the
protein near the loop corresponding to the highly variable region
previously identified in NEU3 and NEU4 [4], supporting the
hypothesis that this portion of the sialidase proteins is more
tolerant to amino acid substitutions. Moreover, 13 out of 16
missense substitutions identified in this study fall in regions
connecting antiparallel beta-strands of NEU1 predicted protein
structure (Table 4). Overall, these results confirm previous studies,
Figure 4. Subcellular localization study of V217A and D234N NEU1 mutant proteins. Confocal microscopy images showing the subcellular
distribution of NEU1 wild-type, V217A and D234N mutants. NEU1 proteins were detected using specific rabbit anti-NEU1 antibody and revealed with
Alexa-555 secondary antibody. Wild-type NEU1 labeling resulted in a vesicular pattern (A), mainly colocalizing with the lysosomal marker LAMP1
detected with mouse anti-LAMP1 and revealed with Alexa-405 secondary antibody (B, merge in C). The V217A (D) and D234N (G) mutant proteins
showed a tubulo-reticular localization. Almost no colocalization between V217A and D234N mutants and LAMP1 (E–F and H–I) could be detected.
Insets represent enlargement of the indicated areas.
doi:10.1371/journal.pone.0104229.g004
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demonstrating that loop regions are less conserved and particularly
subjected to amino acid substitution in sialidase protein family
[4,31].
While most of the functional variants in the NEU1 gene are
rare, with MAF,1%, we also identified one more common
missense substitution (c.263G.C) with global MAF.2%, that is
restricted to the African and African American sub populations
(MAF.7%). The high allele frequency observed only in a single
sub population suggests a founder effect, with the SNV arising in
an ancestor of the subgroup and then spreading within it.
Enzymatic assays showed that this variant does not alter the level
of enzyme activity and it is unlikely that it can influence its
substrate specificity or kinetic parameters, given its position on the
opposite side of the catalytic crevice (Figure 2A and 2B).
Overall, considering the already known pathogenic variants,
together with the two new missense mutations (c.650T.C and
Figure 5. V217A and D234N NEU1 mutant proteins are accumulated in the ER. Confocal microscopy images showing the subcellular
distribution of NEU1 wild-type, V217A and D234N mutants. NEU1 proteins were detected using specific rabbit anti-NEU1 antibody and revealed with
Alexa-555 secondary antibody. Wild-type NEU1 labeling resulted in a vesicular pattern (A), with no evident colocalization with the ER marker PDI
detected with mouse anti-PDI and revealed with Alexa-405 secondary antibody (B, merge in C). The V217A (D) and D234N (G) mutant proteins
showed a tubulo-reticular localization with significant colocalization areas with PDI. Insets represent the GFP signal, indicating transfected cells. No
evident leak of the green signal into the red or blue channel is detected.
doi:10.1371/journal.pone.0104229.g005
New Putative Pathogenic SNVs in NEU1 Sialidase Gene
PLOS ONE | www.plosone.org 10 August 2014 | Volume 9 | Issue 8 | e104229
c.700G.A) and the frameshift insertion c.759_760insGA identi-
fied in this study, we found a total of 6 pathogenic alleles in a
population of 7595 individuals. This results in a carrier frequency
of 1 every 1266 subjects, close to the value of 1 every 1025
expected for sialidosis given the case of Hardy-Weinberg
equilibrium and the estimated incidence of 1/4,200,000 [7].
Given the large number of subjects enrolled in the 1000G and
the ESP6500 sequencing projects, the analysis of these databases is
effective to reveal rare variants in known disease-causing genes
[20,32] that could represent undetected pathological alleles
present in the population [33]. In this study, we searched these
databases for SNVs in NEU1 gene that led to reduced activity of
the enzyme.
Since the two databases contain data from healthy subjects in
their middle age, we presumed that both known and new causative
mutations would be present as rare alleles only in the heterozygous
state. Applying the prioritization strategy described in methods, we
identified 9 missense variants with MAF#0.1% (marked with * in
Table 3) not previously reported as associated with sialidosis in
HGMD database [13], as well as 3 SNVs (rs190549838,
rs104893983, rs28940583) already identified in patients with
sialidosis, with the latter two having an allele frequency of 0.07 and
0.3%, respectively. The fact that MAF value for rs190549838 was
equal to 0 is due to a known issue in the 1000G dataset. We also
identified a novel single frameshift insertion c.759_760insGA that
alters the open reading frame of the wild-type protein from amino
acid 254. Even if we did not test it with functional in vitro assays,
this variant can be considered a pathological mutation, since it
severely affects NEU1 peptide sequence, and also removes
essential catalytic residues R341 and Y370 [2,3].
None of the 9 missense variants described above affects amino
acids which are located near the active site in the generated NEU1
structure model. However, 7 of these residues (P210, V217, T222,
D234, G248, G252, S351) are positioned in a region that is
possibly involved in the NEU1-PPCA interaction, according to
structural modeling of NEU1 pathological mutations [28]
(Figure 2A and 2B).
We further characterized the 9 newly identified missense
variants for their impact on lysosomal sialidase enzymatic activity
and subcellular localization. The individual NEU1 mutants were
co-expressed with the human PPCA cDNA, which is essential for
the proper compartmentalization and catalytic activation of wild-
type NEU1 [2,12]. We found that the majority of the analyzed
NEU1 variants maintain the properties of the wild-type enzyme,
are correctly glycosylated and thus potentially as active as the wild-
type enzyme in our expression model [29]. To avoid bias in
sialidase activity, only experiments with homogeneous transfection
efficiency of the NEU1 and PPCA constructs were subjected to
enzymatic activity assays. This study allowed the identification of
two variants, namely c.650T.C (p.V217A) and c.700G.A
(p.D234N), showing significantly lower sialidase activity compared
to the wild-type protein (Figure 3A).
Characterization of the V217A and D234N mutant
proteins
A precise measurement of the sialidase activity of the V217A
and D234N protein variants is essential to evaluate their role as
defective enzymes causative for sialidosis [1,5,6]. We thus decided
to apply the normalization strategy described in methods to obtain
a robust estimation of enzyme specific activity for the two
candidate pathological mutants (Figure 3 and Figure S1).
The c.650T.C mutant showed a 44% residual activity
compared to the wild-type enzyme. Even if the residual activity
is still quite high compared to non-transfected cells, the mutation
results in the p.V217A amino acid change, involving the same
residue of the p.V217M substitution already described in a patient
carrying sialidosis type I [34] and present in the HGMD database.
This mutation is supposed to alter the interaction between NEU1
and PPCA, thus preventing the correct transport and maturation
of the enzyme [34]. This evidence strongly suggests that also the
c.650T.C mutation may affects the NEU1-PPCA interaction and
could represent a pathological allele responsible for the mild form
of the disease.
The c.700G.A mutant, resulting in the p.D234N amino acid
change, showed a 25% residual activity compared to the wild-type
enzyme. Such a strong reduction is in the range of residual activity
reported for many other pathological mutations already identified
in NEU1 gene [5,8,9].
Based on NEU1 3D model, both p.V217A and p.D234N are
located in the same protein region containing the other already
known pathological mutations predicted to affect the NEU1-
PPCA interaction [28] (Figure 2B). In particular the two residues
V217 and D234, together with the residues G218, L231, W240,
G243 and A298 define a region of the NEU1 protein that could
represent an important site in the surface interaction with PPCA
partner (Figure 2C). As already described in another case of
sialidosis [34], both mutants showed reduced NEU1 protein levels
by Western-blot analysis (Figure 3B) which correlate with the
reduction in sialidase activity. Moreover, their subcellular local-
ization resulted altered compared to the wild-type protein and the
mutant NEU1 proteins showed almost no signal in vesicular
structures compatible with the lysosomal compartment (Figure 4).
Instead, V217A and D234N mutant proteins were mainly
localized in the ER (Figure 5), supporting the idea of an altered
protein trafficking that probably results in protein degradation.
Overall, Western-blot and subcellular localization data suggest
that p.V217A and p.D234N substitutions could play a role in the
NEU1-PPCA interaction/recognition, a well known pivotal step
for the correct localization of the sialidase enzyme [2,12,28] and/
or cause a reduced stability of the protein.
In this perspective, both mutants represent new putative
pathological mutations causative for sialidosis, at least in the late
onset form of the disease. Given the emerging role of NEU1 in
several multifactorial diseases [14–19], the identification of new
protein variants with altered enzymatic activity could be of interest
for future studies aimed at investigating the involvement of NEU1
functional variants in the pathogenesis of complex disorders.
Conclusions
The use of genomic data from large sequencing programs is an
effective strategy to investigate genetic variability in humans. This
study led to the identification of previously unknown NEU1 alleles
diffused in the actual population. These data are useful for future
functional studies on human sialidase enzymes. In vitro functional
studies on variants occurring in NEU1 gene also led to the
identification of two new putative disease-causing mutations
responsible for sialidosis. In summary, we identified a total of 3
known and 3 novel putative sialidosis disease alleles in a cohort of
7595 individuals, a number compatible with the estimated
prevalence of the disease. The discovery of rare variant based
on large genomic dataset, combined with well established
functional test in cellular models, prove to be an effective strategy
to identify new causative mutations in known disease genes and to
assess their functional impact.
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Supporting Information
Figure S1 Evaluation of PPCA protein level in cells
transfected with V217A and D234N mutant proteins.
Immunoblotting analysis on NEU1 wt, V217A and D234N cell
extracts deriving from different experiments. The amount of
PPCA protein was evaluated in each of the 8 biological replicates
and only the 5 samples showing an homogeneous level of the
protein were considered (see Methods). Numbers show the relative
normalized amount of PPCA protein from densitometric analysis,
calculated as described in Methods.
(TIF)
Figure S2 Nucleotide variants identified in NEU1 cDNA.
The complete sequence of NEU1 cDNA (NM_000434.3) is
reported, with ORF in uppercase. Numbering of relevant
nucleotides, starting from the ATG, is reported in superscript.
Both starting ATG and stop codon TGA are underlined. The
functional nucleotide variants (missense or LoF) are reported in
bracket (reference base/variant allele): in magenta, already known
disease mutations for sialidosis; in red, the 3 variants identified in
this work as new putative pathological alleles; in green, the other
variants tested by functional assays; in light blue, the remaining
untested variants.
(PDF)
File S1 Supporting tables. Table S1, Oligonucleotide
primers used for PCR amplification and mutagenesis.
Table S2, Allele frequencies and genotype counts for
NEU1 missense variants from ESP6500 database. Table
S3, Allele frequencies and genotype counts for NEU1
missense variants from 1000G database.
(PDF)
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